Kura Oncology Inc. Common Stock (KURA)

About KURA

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tum…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

260

Website

www.kuraoncology.com/

Fundamentals

1-day range

$12.89$13.36

Market cap

$815.84M

P/E (trailing)

—

P/E (forward)

-5.85

EPS (trailing)

$-3.35

Dividend yield

—

Beta

0.48

Avg. volume

1.84M

Forecasts

12 analyst ratings

Kura Oncology Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• KURA

  Kura Oncology Inc. Common Stock

  $12.65

  ▼ 4.06%
  Market cap $815.84MP/E —
  $7.36$13.9
• GERN

  Geron Corporation Common Stock

  $1.51

  ▼ 1.63%
  Market cap $821.15MP/E —
  $1.04$2.01
• DSGN

  Design Therapeutics Inc. Common Stock

  $15.12

  ▼ 0.85%
  Market cap $796.95MP/E —
  $5.04$17.25
• ACRS

  Aclaris Therapeutics Inc. Common Stock

  $6.01

  ▼ 2.44%
  Market cap $772.34MP/E —
  $1.74$6.6
• ANNX

  Annexon Inc. Common Stock

  $4.97

  ▼ 5.33%
  Market cap $860.17MP/E —
  $2.03$7.18
• PHAR

  Pharming Group N.V. ADS each representing 10 ordinary shares

  $11.7

  ▼ 0.68%
  Market cap $766.28MP/E 88.15
  $0.8338$1.82
• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $747.88MP/E —
  $32.04$124.82

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

82.36M

Total value held

$658.67M

Institutional holders

210